Heron Therapeutics Inc HRTX Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.29 up $0.01, 4.04% on Nov 6
Last price · Previous close $0.28
- Market cap
- At the last price
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.18Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.29up $0.01, 4.04%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.28Nov 5
- Volume1.33MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.74MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.26 to $1.58; now $0.29
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the last price. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
HRTX trailed the S&P 500 in all 7 periods.
| Period | HRTX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | HRTX: down 12.2% S&P 500: down 5.6% | HRTX trailed the S&P 500 by 6.6 percentage points Trailed |
| 3M | HRTX: down 41.6% S&P 500: down 4.1% | HRTX trailed the S&P 500 by 37.5 percentage points Trailed |
| YTD | HRTX: down 77.6% S&P 500: up 8.7% | HRTX trailed the S&P 500 by 86.3 percentage points Trailed |
| 1Y | HRTX: down 73.5% S&P 500: up 10.9% | HRTX trailed the S&P 500 by 84.4 percentage points Trailed |
| Long term | ||
| 3Y | HRTX: down 60.6% S&P 500: up 75.0% −26.7% vs +20.5% a year | HRTX trailed the S&P 500 by 135.6 percentage points Trailed |
| 5Y | HRTX: down 97.7% S&P 500: up 67.8% −52.9% vs +10.9% a year | HRTX trailed the S&P 500 by 165.5 percentage points Trailed |
| 10Y | HRTX: down 98.0% S&P 500: up 313.1% −32.5% vs +15.2% a year | HRTX trailed the S&P 500 by 411.1 percentage points Trailed |
$10,000 invested in HRTX 10 years ago (Nov 4, 2016) would be worth about $196 as of , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
HRTX trailed the S&P 500 in all 7 periods.
| Period | HRTX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | HRTX: down 12.2% S&P 500: down 5.6% | HRTX trailed the S&P 500 by 6.6 percentage points Trailed |
| 3M | HRTX: down 41.6% S&P 500: down 4.3% | HRTX trailed the S&P 500 by 37.3 percentage points Trailed |
| YTD | HRTX: down 77.6% S&P 500: up 7.8% | HRTX trailed the S&P 500 by 85.4 percentage points Trailed |
| 1Y | HRTX: down 73.5% S&P 500: up 9.7% | HRTX trailed the S&P 500 by 83.2 percentage points Trailed |
| Long term | ||
| 3Y | HRTX: down 60.6% S&P 500: up 68.8% −26.7% vs +19.1% a year | HRTX trailed the S&P 500 by 129.4 percentage points Trailed |
| 5Y | HRTX: down 97.7% S&P 500: up 56.9% −52.9% vs +9.4% a year | HRTX trailed the S&P 500 by 154.6 percentage points Trailed |
| 10Y | HRTX: down 98.0% S&P 500: up 252.6% −32.5% vs +13.4% a year | HRTX trailed the S&P 500 by 350.6 percentage points Trailed |
$10,000 invested in HRTX 10 years ago (Nov 4, 2016) would be worth about $196 as of , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$1,270.40
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Aug 27, 1987.
Stock splits
2
Latest: 1-for-20 on . Share counts adjust after each split.
Both splits
- 1-for-20
- 1-for-4
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $151.18Mup 1.0%
- Net income
- −$34.05M
- Diluted EPS
- −$0.18
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $32.81M | −$4.85M | −$0.03 |
| Q4 FY24 (Dec 31, 2024) | $40.78M | $3.66M | $0.02 |
| Q1 FY25 (Mar 31, 2025) | $38.90M | $2.64M | $0.01 |
| Q2 FY25 (Jun 30, 2025) | $37.20M | −$2.38M | −$0.02 |
| Q3 FY25 (Sep 30, 2025) | $38.21M | −$17.50M | −$0.10 |
| Q4 FY25 (Dec 31, 2025) | $40.59M | −$2.95M | −$0.01 |
| Q1 FY26 (Mar 31, 2026) | $34.71M | −$8.11M | −$0.04 |
| Q2 FY26 (Jun 30, 2026) | $37.67M | −$5.49M | −$0.03 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $86.35M | −$220.68M | −$2.24 |
| FY22 (Dec 31, 2022) | $107.67M | −$182.02M | −$1.67 |
| FY23 (Dec 31, 2023) | $127.04M | −$110.56M | −$0.80 |
| FY24 (Dec 31, 2024) | $144.29M | −$13.58M | −$0.09 |
| FY25 (Dec 31, 2025) | $154.90M | −$20.20M | −$0.12 |
Margins
- Gross 70.1%
- Operating −7.2%
- Net −22.5%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$12.09MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$11.61MLast 12 months
- Capital spending$484.00KLast 12 months
- −8.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $18.51MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $42.66MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$148.35MAs of Jun 30, 2026
- Net debt$105.69MAs of Jun 30, 2026
- 2.49As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 21.48As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −300.9%Last 12 months
Over the last 12 months, Heron Therapeutics lost money: its net loss was 300.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −13.6%Last 12 months
Over the last 12 months, Heron Therapeutics’s net loss was 13.6% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Heron Therapeutics Inc
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
HRTX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
HRTX stock FAQ
What is HRTX stock’s price today?
Heron Therapeutics (HRTX) traded at $0.29 as of , up $0.01 (4.04%) from the previous close of $0.28. Over the past 52 weeks it has traded between $0.26 and $1.58.
If you invested $1,000 in HRTX 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in HRTX on would be worth about $20 as of , a total return of −98.0%. The same $1,000 would be worth $23 if invested five years ago, $265 if invested one year ago, $3 if invested 20 years ago, and $0 if invested 30 years ago. Past performance doesn’t predict future returns.
What is HRTX’s P/E ratio?
HRTX’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.18).
How much revenue does Heron Therapeutics make?
Heron Therapeutics reported $151.2 million of revenue over the four quarters to , up 1.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $37.7 million, up 1.3% from a year earlier.
Is Heron Therapeutics profitable?
Not over the four quarters to . Heron Therapeutics reported a net loss of $34.0 million across those four quarters on $151.2 million of revenue.
What are HRTX’s earnings per share?
HRTX’s diluted earnings per share were −$0.18 over the four quarters to , compared with −$0.02 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.03 per share, against −$0.02 a year earlier (how EPS works).
Does HRTX pay a dividend?
Heron Therapeutics hasn’t paid a dividend in the last twelve months.
What is HRTX’s 52-week high and low?
Over the past 52 weeks HRTX has traded as low as $0.26 and as high as $1.58. At $0.29 as of , it is 81.5% below that high and 11.6% above the low.
What is HRTX’s all-time high?
HRTX’s highest closing price was $1,270.40 on , adjusted for stock splits. At $0.29 as of , it is 100.0% below that record.
Has HRTX stock ever split?
Yes, twice: 1-for-4 on ; 1-for-20 on .
How has HRTX stock performed?
Including dividends and measured to the last price on , HRTX has returned −77.6% so far this year and −73.5% over the past year, and −97.7% over five years (−52.9% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Heron Therapeutics in?
Heron Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does HRTX trade on?
Heron Therapeutics trades on the Nasdaq under the ticker symbol HRTX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.